Table 2.
Statistical analysis of 38 differential metabolites in serum identified from the comparison of HSPN (+) vs. HSPN (–).
Differential metabolites | Retention time (min) | Mass-to-charge ratio | VIP | Fold change | p-valuea | Adjusted p-valueb | Adduct |
---|---|---|---|---|---|---|---|
Oxalacetic acid | 0.95 | 133.0135 | 2.70 | 2.14 | <0.001 | <0.001 | M+H |
PE-NMe (16:1/18:3) | 7.28 | 726.5133 | 2.56 | 1.81 | <0.001 | <0.001 | M+H |
2-Methyl-3-pentenoic acid | 1.89 | 132.1014 | 2.45 | 1.34 | <0.001 | <0.001 | M+NH4 |
PE-NMe2 (18:4/14:0) | 6.62 | 712.4977 | 2.47 | 1.81 | <0.001 | <0.001 | M+H |
Eicosapentaenoic acid* | 7.25 | 303.2329 | 2.35 | 7.02 | <0.001 | <0.001 | M+H |
7-Hydroxyeicosatetraenoic acidc | 6.52 | 319.2283 | 2.30 | 7.50 | <0.001 | <0.001 | M–H |
PS (14:0/24:0) | 7.13 | 820.6026 | 2.29 | 1.38 | <0.001 | <0.001 | M+H |
TG (18:4/14:1/20:5) | 7.04 | 865.6317 | 2.27 | 1.38 | <0.001 | <0.001 | M+Na |
Glycerophosphocholine | 0.66 | 280.0938 | 2.18 | 0.65 | <0.001 | <0.001 | M+Na |
PC (14:1/P-16:0) | 7.52 | 688.5217 | 2.23 | 1.35 | <0.001 | <0.001 | M+H |
Linoleyl carnitine | 6.15 | 424.344 | 2.22 | 1.80 | <0.001 | <0.001 | M+H |
PC (22:6/24:1) | 6.52 | 938.6656 | 2.17 | 1.37 | <0.001 | <0.001 | M+Na |
PE (P-18:1/14:0) | 6.96 | 674.5069 | 2.14 | 1.34 | <0.001 | <0.001 | M+H |
5b-Cholestane-3a,7a,12a,23-Tetrol | 11.04 | 437.3639 | 2.11 | 0.58 | <0.001 | <0.001 | M+H |
PS (22:6/24:1) | 11.79 | 935.6486 | 2.10 | 0.76 | <0.001 | <0.001 | M+NH4 |
8alpha-Hydroxy-gama-tocopherone | 10.41 | 433.3692 | 2.09 | 0.61 | <0.001 | <0.001 | M+H |
6,10,14-Trimethyl-5,9,13- | 11.90 | 263.2382 | 2.08 | 0.42 | <0.001 | <0.001 | M+H |
Pentadecatrien-2-one | |||||||
Phenylpropiolic acid | 1.25 | 147.0443 | 2.04 | 1.32 | <0.001 | <0.001 | M+H |
Cystathionine ketimine | 3.04 | 204.0329 | 2.04 | 1.25 | <0.001 | <0.001 | M+H |
2-Hydroxyhexadecanoylcarnitine | 6.47 | 426.3589 | 1.97 | 1.66 | <0.001 | <0.001 | M+H |
Ribothymidinec | 0.64 | 257.0788 | 1.96 | 1.73 | <0.001 | <0.001 | M–H |
Cinnamic acid | 3.04 | 149.0594 | 1.95 | 1.16 | <0.001 | <0.001 | M+H |
6Z,9Z-octadecadienoic acid | 10.70 | 281.2483 | 1.94 | 0.62 | <0.001 | <0.001 | M+H |
Choline* | 0.65 | 104.1074 | 1.89 | 1.46 | <0.001 | <0.001 | M+H |
Dihydroxyacetonec | 0.65 | 89.02451 | 1.88 | 1.63 | <0.001 | <0.001 | M–H |
β-Pseudouridinec* | 1.29 | 243.0626 | 1.82 | 1.44 | <0.001 | <0.001 | M–H |
Cis-vaccenic acid* | 8.59 | 300.2904 | 1.77 | 1.26 | <0.001 | <0.001 | M+NH4 |
LysoPA (20:4/0:0)c | 6.65 | 457.2372 | 1.76 | 2.28 | <0.001 | <0.001 | M–H |
5-(3-methoxyphenyl)-4-(sulfooxy) | 0.58 | 327.0523 | 1.64 | 1.29 | <0.001 | <0.001 | M+Na |
Pentanoic acid | |||||||
L-Carnitine* | 0.67 | 162.1129 | 1.64 | 0.82 | <0.001 | <0.001 | M+H |
Tryptophyl-Phenylalanine | 4.63 | 352.1637 | 1.62 | 0.70 | <0.001 | <0.001 | M+H |
PE (P-16:0e/0:0) | 7.05 | 438.2994 | 1.62 | 1.65 | <0.001 | <0.001 | M+H |
Benzoic acid | 1.69 | 123.0436 | 1.62 | 1.25 | <0.001 | <0.001 | M+H |
Galbanic acidc | 5.36 | 397.2054 | 1.52 | 0.55 | <0.001 | <0.001 | M–H |
LysoPC (15:0)* | 7.83 | 482.3255 | 1.51 | 1.47 | <0.001 | <0.001 | M+H |
3-Pyridinebutanoic acidc | 2.87 | 164.0721 | 1.46 | 1.31 | <0.001 | 0.001 | M–H |
1-Pyrroline-4-hydroxy-2-Carboxylatec | 0.68 | 128.0356 | 1.44 | 1.47 | <0.001 | <0.001 | M–H |
Aminocaproic acidc | 1.23 | 130.0877 | 1.35 | 1.24 | 0.008 | 0.034 | M–H |
means that the metabolites were confirmed with reference compounds.
The metabolites were listed in a decreasing order based on variable importance in the projection (VIP) values.
Fold change with a value >1 indicates a relatively higher concentration present in the HSPN (+) patients.
p-values from Mann–Whitney U-test;
Adjusted by false discovery rate correction across all the metabolites within the comparison.
means that the metabolite was detected in the negative ion mode. PE, Phosphatidylethanolamine; PS, Phosphatidylserine; TG, Triglyceride; PC, Phosphatidylcholine; LysoPA, Lysophosphatidic acid; LysoPC, lysophosphatidylcholine.